Integra LifeSciences (NASDAQ:IART) Shares Up 6.6% – Time to Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price was up 6.6% during trading on Thursday . The stock traded as high as $18.54 and last traded at $18.53. Approximately 176,432 shares were traded during mid-day trading, a decline of 80% from the average session volume of 897,408 shares. The stock had previously closed at $17.38.

Analyst Ratings Changes

IART has been the topic of a number of research reports. Wells Fargo & Company boosted their target price on shares of Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. BMO Capital Markets assumed coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target on the stock. UBS Group initiated coverage on Integra LifeSciences in a report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price target on the stock. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Thursday, June 18th. Finally, Citigroup restated a “neutral” rating and issued a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $18.86.

Integra LifeSciences Trading Up 5.6%

The company has a market cap of $1.43 billion, a PE ratio of -203.64, a P/E/G ratio of 1.46 and a beta of 1.21. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. The business’s 50-day simple moving average is $17.98 and its 200-day simple moving average is $13.76.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The company had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, analysts expect that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC bought a new position in shares of Integra LifeSciences in the fourth quarter valued at approximately $25,000. Osaic Holdings Inc. boosted its holdings in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after buying an additional 1,104 shares during the period. Tower Research Capital LLC TRC grew its stake in Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after buying an additional 6,814 shares during the last quarter. Virtu Financial LLC bought a new position in Integra LifeSciences in the 4th quarter worth $124,000. Finally, Sequoia Financial Advisors LLC raised its holdings in Integra LifeSciences by 27.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock worth $134,000 after acquiring an additional 3,059 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.